Emily M Garabedian

Title: Emily M Garabedian: Innovator in Prostate Cancer Research

Introduction

Emily M Garabedian is a prominent inventor based in St. Louis, MO (US). She has made significant contributions to the field of cancer research, particularly in understanding prostate cancer through innovative models. Her work has implications for both research and therapeutic strategies in oncology.

Latest Patents

Emily M Garabedian holds a patent for a transgenic mouse model of prostate cancer. This model discloses transgenic mice that produce prostate tumors, faithfully recapitulating many features of human prostatic carcinoma. The invention utilizes transcriptional regulatory elements active in Paneth cells, granule goblet cells, and intermediate cells to express Simian Virus 40 large T antigen (TAg) in transgenic mice, leading to the development of prostate tumors. The mice develop prostatic intraepithelial neoplasia (PIN) at an early age, with progression marked by local invasion, loss of androgen-dependence, and eventual metastases. The patent highlights several important characteristics of the transgenic mice, including the full penetrance of the disease and the normal lifespan of the female transgenic mice.

Career Highlights

Emily M Garabedian is affiliated with Washington University, where she conducts her research. Her work has been instrumental in advancing the understanding of prostate cancer and developing models that can be used for further research and drug testing.

Collaborations

Emily collaborates with Jeffrey I Gordon, a fellow researcher, to enhance the impact of her work in the field of cancer research.

Conclusion

Emily M Garabedian's innovative contributions to prostate cancer research through her patented transgenic mouse model exemplify her commitment to advancing medical science. Her work continues to pave the way for future discoveries in oncology.